Solid Biosciences Inc. (SLDB)
Form 4 sales, Form 144 notices and lockup dates
- Latest sale
- $97k
- Feb 18 · Routine
- Form 4 sales
- 83
- On record
- Form 144 notices
- 2
- Proposed sales
- Next unlock
- None
- No lockup ahead
Lockups
No lockup on record.
Sales by reason
Timeline
- 1 Form 4 saleUnusualFeb 4 2026
Sold 48,913 shares at $6.44 ($315k)
Cumbo Alexander, President and CEO
10b5-1 planSold 18.1% of holdings ($1.7M position)222,018 shares left4.4x usual sizeFiling
- 2 Form 4 saleUnusualFeb 4 same day
Sold 18,894 shares at $6.44 ($122k)
Howton David T, Chief Operating Officer
10b5-1 planSold 16.2% of holdings ($752k position)97,859 shares left3.6x usual sizeFiling
- 3 Form 4 saleRoutineFeb 18 +14 days
Sold 5,404 shares at $5.82 ($31k)
Tan Kevin, CFO & Treasurer
10b5-1 planSold 5.2% of holdings ($610k position)99,422 shares left0.9x usual sizeFiling
- 4 Form 4 saleRoutineFeb 18 same day
Sold 7,469 shares at $5.82 ($43k)
Howton David T, Chief Operating Officer
10b5-1 planSold 6.6% of holdings ($655k position)105,077 shares left1.3x usual sizeFiling
- 5 Form 4 saleRoutineFeb 18 same day
Sold 3,616 shares at $5.82 ($21k)
Herzich Paul, Chief Technology Officer
10b5-1 planSold 4.7% of holdings ($444k position)72,638 shares left1.3x usual sizeFiling
- 6 Form 4 saleRoutineFeb 18 same day
Sold 2,658 shares at $5.82 ($15k)
Ganot Ilan, Director
10b5-1 planSold 8.8% of holdings ($175k position)27,474 shares left2.5x usual sizeFiling
- 7 Form 4 saleRoutineFeb 18 same day
Sold 4,134 shares at $5.82 ($24k)
Hanrahan Jessie, Chief Regulatory Officer
10b5-1 planSold 5.3% of holdings ($457k position)74,318 shares left0.9x usual sizeFiling
- 8 Form 4 saleRoutineFeb 18 same day
Sold 16,644 shares at $5.82 ($97k)
Cumbo Alexander, President and CEO
10b5-1 planSold 6.6% of holdings ($1.5M position)235,405 shares left1.5x usual sizeFiling
Every transaction
Loading transactions…
Sales, notices and lockups (85)
Export watchlist as CSV| Source | ||||||||
|---|---|---|---|---|---|---|---|---|
| Feb 18, 2026 | Cumbo Alexander | President and CEO | Form 4 sale | 16,644 | $97k | 6.6% | Routine | SEC |
| Feb 18, 2026 | Hanrahan Jessie | Chief Regulatory Officer | Form 4 sale | 4,134 | $24k | 5.3% | Routine | SEC |
| Feb 18, 2026 | Ganot Ilan | Director | Form 4 sale | 2,658 | $15k | 8.8% | Routine | SEC |
| Feb 18, 2026 | Herzich Paul | Chief Technology Officer | Form 4 sale | 3,616 | $21k | 4.7% | Routine | SEC |
| Feb 18, 2026 | Howton David T | Chief Operating Officer | Form 4 sale | 7,469 | $43k | 6.6% | Routine | SEC |
| Feb 18, 2026 | Tan Kevin | CFO & Treasurer | Form 4 sale | 5,404 | $31k | 5.2% | Routine | SEC |
| Feb 4, 2026 | Howton David T | Chief Operating Officer | Form 4 sale | 18,894 | $122k | 16.2% | Unusual | SEC |
| Feb 4, 2026 | Cumbo Alexander | President and CEO | Form 4 sale | 48,913 | $315k | 18.1% | Unusual | SEC |
| Feb 4, 2026 | Ganot Ilan | Director | Form 4 sale | 7,205 | $46k | 22.2% | Unusual | SEC |
| Feb 4, 2026 | Tan Kevin | CFO & Treasurer | Form 4 sale | 14,783 | $95k | 13.6% | Unusual | SEC |
| Feb 4, 2026 | Brooks Gabriel | Chief Medical Officer | Form 4 sale | 12,616 | $81k | 13.0% | Unusual | SEC |
| Feb 4, 2026 | Hanrahan Jessie | Chief Regulatory Officer | Form 4 sale | 12,348 | $80k | 14.9% | Routine | SEC |
| Feb 4, 2026 | Herzich Paul | Chief Technology Officer | Form 4 sale | 10,905 | $70k | 13.6% | Unusual | SEC |
| Feb 2, 2026 | Tan Kevin | CFO & Treasurer | Form 4 sale | 26,837 | $173k | 19.8% | Unusual | SEC |
| Feb 2, 2026 | Cumbo Alexander | President and CEO | Form 4 sale | 80,258 | $517k | 22.9% | Unusual | SEC |
| Feb 2, 2026 | Hanrahan Jessie | Chief Regulatory Officer | Form 4 sale | 26,535 | $171k | 24.3% | Unusual | SEC |
| Feb 2, 2026 | Brooks Gabriel | Chief Medical Officer | Form 4 sale | 28,335 | $182k | 22.7% | Unusual | SEC |
| Feb 2, 2026 | Howton David T | Chief Operating Officer | Form 4 sale | 37,771 | $243k | 24.4% | Unusual | SEC |
| Feb 2, 2026 | Herzich Paul | Chief Technology Officer | Form 4 sale | 26,250 | $169k | 24.7% | Unusual | SEC |
| Jan 28, 2026 | Ganot Ilan | Director | Form 4 sale | 191 | $1k | 1.1% | Routine | SEC |
| Jan 13, 2026 | Tan Kevin | CFO & Treasurer | Form 4 sale | 5,704 | $30k | 11.0% | Routine | SEC |
| Jan 5, 2026 | Ganot Ilan | Director | Form 4 sale | 1,053 | $6k | 5.7% | No plan | SEC |
| Dec 3, 2025 | Howton David T | Chief Operating Officer | Form 4 sale | 4,932 | $25k | 13.0% | Routine | SEC |
| Dec 3, 2025 | Cumbo Alexander | President and CEO | Form 4 sale | 10,808 | $55k | 11.7% | Routine | SEC |
| Dec 3, 2025 | Hanrahan Jessie | Chief Regulatory Officer | Form 4 sale | 4,483 | $23k | 14.4% | Routine | SEC |
| Dec 3, 2025 | Herzich Paul | Chief Technology Officer | Form 4 sale | 2,701 | $14k | 9.2% | Routine | SEC |
| Nov 10, 2025 | Ganot Ilan | Director | Form 4 sale | 3,278 | $14k | 3.3% | Unusual | SEC |
| Oct 20, 2025 | Brooks Gabriel | Chief Medical Officer | Form 4 sale | 2,895 | $17k | 7.9% | No plan | SEC |
| Feb 14, 2025 | Hanrahan Jessie | Chief Regulatory Officer | Form 4 sale | 3,079 | $12k | 13.8% | Routine | SEC |
| Feb 14, 2025 | Brooks Gabriel | Chief Medical Officer | Form 4 sale | 3,256 | $13k | 12.5% | Routine | SEC |
| Feb 14, 2025 | Tan Kevin | CFO & Treasurer | Form 4 sale | 3,164 | $13k | 8.9% | Routine | SEC |
| Feb 14, 2025 | Herzich Paul | Chief Technology Officer | Form 4 sale | 2,688 | $11k | 12.8% | Routine | SEC |
| Feb 14, 2025 | Cumbo Alexander | President and CEO | Form 4 sale | 11,365 | $45k | 15.8% | Routine | SEC |
| Feb 14, 2025 | Ganot Ilan | Director | Form 4 sale | 1,711 | $7k | 10.3% | Unusual | SEC |
| Feb 14, 2025 | Howton David T | Chief Operating Officer | Form 4 sale | 5,561 | $22k | 18.3% | Routine | SEC |
| Jan 28, 2025 | Ganot Ilan | Director | Form 4 sale | 144 | $448 | 1.2% | Routine | SEC |
| Jan 10, 2025 | Tan Kevin | CFO & Treasurer | Form 4 sale | 4,073 | $16k | 14.1% | No plan | SEC |
| Jan 6, 2025 | Ganot Ilan | Director | Form 4 sale | 1,056 | $5k | 8.4% | No plan | SEC |
| Dec 4, 2024 | Howton David T | Officer | Form 144 notice | 5,072 | $28k | Notice | SEC | |
| Dec 3, 2024 | Hanrahan Jessie | Chief Regulatory Officer | Form 4 sale | 4,610 | $26k | 24.5% | No plan | SEC |
| Dec 3, 2024 | Cumbo Alexander | President and CEO | Form 4 sale | 11,114 | $62k | 22.4% | No plan | SEC |
| Dec 3, 2024 | Howton David T | Chief Operating Officer | Form 4 sale | 5,072 | $28k | 24.5% | No plan | SEC |
| Dec 3, 2024 | Herzich Paul | Chief Technology Officer | Form 4 sale | 2,777 | $16k | 18.6% | No plan | SEC |
| Dec 3, 2024 | Cumbo Alexander | Officer, Director | Form 144 notice | 10,687 | $62k | Notice | SEC | |
| Oct 21, 2024 | Brooks Gabriel | Chief Medical Officer | Form 4 sale | 2,923 | $19k | 21.0% | No plan | SEC |
| May 2, 2024 | Ganot Ilan | Director | Form 4 sale | 462 | $5k | 4.6% | No plan | SEC |
| Jan 29, 2024 | Ganot Ilan | Director | Form 4 sale | 139 | $1k | 1.6% | No plan | SEC |
| Jan 9, 2024 | Tan Kevin | CFO & Treasurer | Form 4 sale | 3,935 | $32k | 29.7% | Unusual | SEC |
| Jan 3, 2024 | Ganot Ilan | Director | Form 4 sale | 1,142 | $6k | 12.3% | No plan | SEC |
| Dec 4, 2023 | Cumbo Alexander | President and CEO | Form 4 sale | 11,757 | $33k | 40.3% | Unusual | SEC |
| Dec 4, 2023 | Howton David T | Chief Operating Officer | Form 4 sale | 5,367 | $15k | 41.1% | Unusual | SEC |
| Dec 4, 2023 | Herzich Paul | Chief Technology Officer | Form 4 sale | 2,968 | $8k | 41.0% | Unusual | SEC |
| Dec 4, 2023 | Hanrahan Jessie | Chief Regulatory Officer | Form 4 sale | 4,879 | $14k | 41.1% | Unusual | SEC |
| Dec 4, 2023 | Marlowe Jennifer | CSO | Form 4 sale | 4,890 | $14k | 41.1% | Unusual | SEC |
| May 2, 2023 | Ganot Ilan | Director | Form 4 sale | 487 | $2k | 10.5% | No plan | SEC |
| Jan 27, 2023 | Morris Carl Ashley | Chief Scientific Officer | Form 4 sale | 441 | $3k | 2.2% | Plan not stated | SEC |
| Jan 27, 2023 | Ganot Ilan | Director | Form 4 sale | 1,523 | $11k | 52.5% | Unusual | SEC |
| Mar 14, 2022 | Morris Carl Ashley | Chief Scientific Officer | Form 4 sale | 22,665 | $25k | 8.2% | Unusual | SEC |
| Mar 14, 2022 | Schneider Joel Solomon Zev | Chief Operating Officer | Form 4 sale | 30,504 | $34k | 11.4% | Unusual | SEC |
| Feb 10, 2022 | Ganot Ilan | CEO & President | Form 4 sale | 463 | $519 | 15.5% | Plan not stated | SEC |
| Mar 12, 2021 | Morris Carl Ashley | Chief Scientific Officer | Form 4 sale | 23,398 | $207k | 7.8% | Plan not stated | SEC |
| Mar 12, 2021 | Schneider Joel Solomon Zev | Chief Operating Officer | Form 4 sale | 23,398 | $207k | 8.0% | Plan not stated | SEC |
| Feb 12, 2021 | Ganot Ilan | CEO & President | Form 4 sale | 457 | $4k | 13.1% | Plan not stated | SEC |
| Jan 28, 2021 | Schneider Joel Solomon Zev | Chief Technology Officer | Form 4 sale | 3,443 | $21k | 1.2% | Plan not stated | SEC |
| Jan 28, 2021 | Ziolkowski Jennifer Lynn | CFO, Treasurer & Asst. Secy | Form 4 sale | 3,473 | $21k | 1.0% | Plan not stated | SEC |
| Jan 28, 2021 | Morris Carl Ashley | Chief Scientific Officer | Form 4 sale | 3,459 | $21k | 1.1% | Plan not stated | SEC |
| Jan 28, 2021 | Ganot Ilan | CEO & President | Form 4 sale | 10,713 | $66k | 0.9% | Plan not stated | SEC |
| Aug 13, 2020 | Ganot Ilan | CEO & President | Form 4 sale | 299 | $730 | 7.9% | Plan not stated | SEC |
| Jul 28, 2020 | Schneider Joel Solomon Zev | Chief Technology Officer | Form 4 sale | 4,041 | $10k | 1.4% | Plan not stated | SEC |
| Jul 28, 2020 | Morris Carl Ashley | Chief Scientific Officer | Form 4 sale | 3,591 | $9k | 1.2% | Plan not stated | SEC |
| Jul 28, 2020 | Ziolkowski Jennifer Lynn | CFO, Treasurer & Asst. Secy | Form 4 sale | 3,591 | $9k | 1.1% | Plan not stated | SEC |
| Jul 28, 2020 | Herscha Lynette | Chief Legal Officer | Form 4 sale | 5,141 | $12k | 3.1% | Plan not stated | SEC |
| Jul 28, 2020 | Ganot Ilan | CEO & President | Form 4 sale | 11,124 | $27k | 1.0% | Plan not stated | SEC |
| May 8, 2019 | Zarur Juan Andrey | Director | Form 4 sale | 8,000 | $80k | 44.0% | Unusual | SEC |
| Mar 28, 2019 | Boxer Capital, LLC | 10% owner | Form 4 sale | 450,000 | $4.4M | 11.5% | Plan not stated | SEC |
| Jan 14, 2019 | Arnold Matthew Bennett | Director | Form 4 sale | 5,000 | $160k | 0.1% | Plan not stated | SEC |
| Jan 7, 2019 | Arnold Matthew Bennett | Director | Form 4 sale | 5,000 | $150k | 0.1% | Plan not stated | SEC |
| Jan 4, 2019 | Amorrortu Pedro Alvaro | Chief Operating Officer | Form 4 sale | 9,000 | $271k | 5.4% | Plan not stated | SEC |
| Dec 3, 2018 | Amorrortu Pedro Alvaro | Chief Operating Officer | Form 4 sale | 9,000 | $280k | 5.1% | Plan not stated | SEC |
| Dec 3, 2018 | Quiroz Jorge Armando | Chief Medical Officer | Form 4 sale | 40,150 | $1.3M | 15.0% | Plan not stated | SEC |
| Nov 16, 2018 | Quiroz Jorge Armando | Chief Medical Officer | Form 4 sale | 100 | $3k | 0.0% | Plan not stated | SEC |
| Nov 16, 2018 | Zarur Juan Andrey | Director | Form 4 sale | 100 | $4k | 0.0% | Plan not stated | SEC |
| Nov 15, 2018 | Ganot Ilan | CEO & President | Form 4 sale | 50,000 | $1.5M | 4.3% | Plan not stated | SEC |
| Nov 15, 2018 | Schneider Joel Solomon Zev | Officer | Form 4 sale | 21,990 | $678k | 14.8% | Plan not stated | SEC |
| Nov 15, 2018 | Amorrortu Pedro Alvaro | Chief Operating Officer | Form 4 sale | 9,000 | $278k | 5.0% | Plan not stated | SEC |